Requests for applications are now open for new collaborations with the Environmental Determinants of Islet Autoimmunity (ENDIA) Study Group and leading experts around the world to answer important unknowns about disease mechanisms with the long-term aim of preventing type 1 diabetes (T1D).

Launched in late 2017, the Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) is designed to carry out newborn screening in the general population, identify infants at high genetic risk of developing type 1 diabetes, and offer them participation in trials to prevent disease initiation.

The goal of this funding opportunity is to accelerate the development of therapies to prevent, slow, halt or reverse the progression of Type 1 Diabetes (T1D) and/or cure established T1D through the advancement of high-impact research carried out by coordinated, multidisciplinary teams.

This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D) to avoid acute complications at diagnosis and to allow earlier interventions to prevent and/or delay clinical manifestations and long term complications of the disease.

This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of novel and supportive technologies for the improvement of cell replacement interventions using novel methods, biomaterials and devices for type 1 diabetes (T1D) treatment.

This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of new approaches to create devices/components with enhanced accuracy and less patient burden that will represent real advancements regarding safety and effectiveness of glucose control technologies and their integration into open and closed loop hormone replacement systems.

This U2C Funding Opportunity Announcement (FOA) is a National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) initiative to establish a novel national Stakeholder Engagement Innovation Center for advancing equity in type 2 diabetes research (SEIC-T2D). A primary goal of the SEIC-T2D is to accelerate equitable engagement of individuals from and communities of diverse backgrounds and sectors in developing the research priorities and activities that involve them, particularly underserved communities, and those with the highest proportion of diabetes-related morbidity and mortality. The SEIC-T2D will provide highly specialized research resources to support field investigators by fully embedding communities, patients, and other stakeholders into the full spectrum of research activities through expert consultations and education in principles and methods of community-engaged research. The SEIC-T2D will also establish a network consisting of multidisciplinary research investigators, including from underrepresented groups, with expertise in T2D and community-engaged methods, community experts with lived experiences, and representatives of various health and other organizations deemed essential for addressing disparities and advancing health equity in T2D prevention and treatment.

This U2C funding opportunity announcement (FOA) is a National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) initiative to establish a novel national Stakeholder Engagement Innovation Center for advancing equity in type 1 diabetes research (SEIC-T1D). A primary goal of the SEIC-T1D is to accelerate equitable engagement of diverse stakeholders (specifically people from NIH designated health disparities populations) in T1D research; particularly those from communities that experience diabetes-related health disparities and live within the healthcare and social systems that negatively impact community members’ and patients’ health. The SEIC-T1D will provide highly specialized research resources to support investigators by fully embedding communities, people living with T1D, and other stakeholders into the full spectrum of research activities through expert consultations and education in principles and methods of community-engaged research. The SEIC-T1D will also establish a network consisting of diverse, multidisciplinary research investigators with expertise in T1D and community-engaged methods, community experts with lived experiences, and representatives of various health and other organizations deemed essential for addressing disparities and advancing health equity in T1D early detection and treatment.